Gazyva and Hyperthyroidism - a phase IV clinical study of FDA data
Summary:
We study 31,302 people who take Gazyva (obinutuzumab) or have Hyperthyroidism. No report of Hyperthyroidism is found in people who take Gazyva.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Gazyva?
Gazyva has active ingredients of obinutuzumab. eHealthMe is studying from 4,470 Gazyva users. Check the latest studies of Gazyva.
What is Hyperthyroidism?
Hyperthyroidism (over activity of the thyroid gland) is found to be associated with 995 drugs and 1,435 conditions by eHealthMe. Check the latest studies of Hyperthyroidism.
No report is found.
Do you take Gazyva and have Hyperthyroidism?
- Check whether Hyperthyroidism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Gazyva:
- Gazyva (4,470 reports)
Hyperthyroidism treatments and more:
- Hyperthyroidism (26,832 reports)
How severe was Hyperthyroidism and when was it recovered:
Expand to all the drugs that have ingredients of obinutuzumab:
Browse all side effects of Gazyva:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Hyperthyroidism:
Browse all the conditions that are associated with Hyperthyroidism:
How the study uses the data?
The study uses data from the FDA. It is based on obinutuzumab (the active ingredients of Gazyva) and Gazyva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Ramipril cause Atrial Tachycardia? - 2 seconds ago
- Gastritis Erosive and drugs of ingredients of iron dextran - 4 seconds ago
- Could Hydrochlorothiazide cause Hiatal Hernia? - 4 seconds ago
- Carafate and Pepcid drug interactions for men aged 50-59 - 4 seconds ago
- Aminoaciduria and drugs of ingredients of acetaminophen - 5 seconds ago
- Could Symbicort cause Retinopathy? - 5 seconds ago
- Veramyst vs. Pataday, side effect and effectiveness comparison - 8 seconds ago
- Benazepril Hydrochloride vs. Verelan Pm, side effect and effectiveness comparison - 10 seconds ago
- Could Reyataz cause Sciatica? - 11 seconds ago
- Candida Sepsis and drugs of ingredients of mesna - 14 seconds ago